Synthon’s SYD985 ADC demonstrates anti-tumor activity, outperforms leading anti-HER2

[News]

Synthon Biopharmaceuticals today announced the results of a head-to-head comparative program of its antibody-drug conjugate (ADC) SYD985 with Roche's market leading anti-HER2 ADC, T-DM1 (Kadcyla).

More... (http://www.news-medical.net/news/20140402/Synthone28099s-SYD985-ADC-demonstrates-anti-tumor-activity-outperforms-leading-anti-HER2-ADC.aspx)